Results 251 to 260 of about 203,317 (299)

Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout

open access: yesArthritis Care &Research, EarlyView.
Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Pascal Richette   +13 more
wiley   +1 more source

Evaluation of a Novel Electric Health Record Sidecar Application to Display Rheumatoid Arthritis Clinical Outcomes During Clinic Visits: Results of a Stepped‐Wedge Cluster Randomized Pragmatic Trial

open access: yesArthritis Care &Research, EarlyView.
Objective We developed a novel electronic health record sidecar application to visualize key rheumatoid arthritis (RA) outcomes, including disease activity, physical function, and pain, via a patient‐facing graphical interface designed for use during outpatient visits (“RA PRO dashboard”).
Gabriela Schmajuk   +16 more
wiley   +1 more source

Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extrarenal Systemic Lupus Erythematosus—A Systematic Review and Meta‐Analysis

open access: yesArthritis Care &Research, EarlyView.
Objective Clinical response to mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug level monitoring (TDM) may help improve treatment efficacy. This systematic review and meta‐analysis examined therapeutic ranges for MPA levels associated with better outcomes and safety in patients with systemic lupus erythematosus (SLE ...
Zahraa Qamhieh   +5 more
wiley   +1 more source

Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs

Life Sciences, 2022
Poor aqueous solubility and poor bioavailability are major issues with many pharmaceutical industries. By some estimation, 70-90% drug candidates in development stage while up-to 40% of the marketed products are poorly soluble which leads to low bioavailability, reduced therapeutic effects and dosage escalation.
Kifayat Ullah, Khan   +5 more
openaire   +4 more sources

PNA solubility enhancers

Tetrahedron Letters, 1998
Abstract Fmoc-protected hydrophilic amino acids were prepared and incorporated into peptide nucleic acid (PNA). N- and C-terminal modification of PNA did not affect its ability to hybridize to complementary nucleic acid targets as determined by dot blot, PNA-FISH and Tm experiments.
Brian D. Gildea   +5 more
openaire   +1 more source

Review on: Solubility Enhancement of Poorly Water Soluble Drugs

Asian Journal of Research in Pharmaceutical Sciences, 2022
About 40% of newly discovered chemicals are lipophilic, and because of their poor solubility in water they are unable to reach the market due to their solubility in water. Solubility is one of the limitations of the oral medication regimen to obtain its required concentration in the circulatory system in order to respond scientifically.
M. H. Markad, S. D. Mankar
openaire   +1 more source

Enhanced Chartreusin Solubility by Hydroxybenzoate Hydrotropy

Journal of Pharmaceutical Sciences, 1979
The apparent aqueous solubility of the water-insoluble cytotoxic agent, chartreusin, was increased at neutral pH in the presence of hydroxybenzoates. Water molecules play an important role in the chartreusin conformation. Studies included solubility and spectral examinations.
G K, Poochikian, J C, Cradock
openaire   +2 more sources

Enhanced hydrogen solubility in niobium films

Physical Review B, 1985
The solubility of hydrogen in niobium films (100--3000 A\r{}) and multilayers of Nb and Pd (20--130 A\r{}) has been studied as a function of film thickness by resistivity and x-ray measurements. The H concentration in solid solution was observed to be greatly enhanced, by a factor of more than 40, as the Nb films were made thinner.
, Moehlecke, , Majkrzak, , Strongin
openaire   +2 more sources

Home - About - Disclaimer - Privacy